Mucoactive medications and airway disease

Paediatric Respiratory Reviews

Volumn 3, Issue 2, 2002, Pages 104-109

  Majima, Yuichi ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Airway; Elasticity; Mucoactive agent; Mucolytic agent; Mucous glycoprotein; Mucus; Viscosity

Indexed keywords

ACETYLCYSTEINE; AMBROXOL; BICARBONATE; BROMHEXINE; CHYMOTRYPSIN; CLARITHROMYCIN; CYSTEINE ETHYL ESTER; DNA; DORNASE ALFA; ERYTHROMYCIN; F ACTIN; GLUCOCORTICOID; GLYCOPROTEIN; MACROLIDE; MESNA; MUCOLYTIC AGENT; PEPTIDE DERIVATIVE; PROTEINASE; SERRATIOPEPTIDASE; SODIUM CHLORIDE; STREPTODORNASE; THIOL DERIVATIVE; TRYPSIN;

ARTICLE; CHRONIC INFLAMMATION; CHRONIC LUNG DISEASE; CILIARY MOTILITY; CLINICAL TRIAL; CONFORMATIONAL TRANSITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG TRANSFORMATION; FLOW KINETICS; GOBLET CELL; HUMAN; MUCOCILIARY CLEARANCE; MUCUS GLAND; MUCUS SECRETION; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT INFECTION; SUBMUCOSA; VISCOELASTICITY;

EID: 0036430213     PISSN: 15260550     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1526-0550(02)00011-2     Document Type: Short Survey

References (44)

1. Lucas A, Douglas LC. Principles underlying ciliary activity in the respiratory tract. Arch Otolaryngol 1934; 20: 518-541.
2. Majima Y, Sakakura Y, Matsubara T, Miyoshi Y. Possible mechanisms of reduction of nasal mucociliary clearance in chronic sinusitis. Clin Otolaryngol 1986; 11: 55-60.
3. Sakakura Y, Ukai K, Majima Y, Murai S, Harada T, Miyoshi Y. Nasal mucociliary clearance under various conditions. Acta Otolaryngol 1983; 96: 167-173.
4. Sakakura Y, Majima Y, Saida S, Miyoshi Y. Reversibility of reduced mucociliary clearance in chronic sinusitis. Clin Otolaryngol 1985; 10: 79-83.
5. Slavin RG. Sinusitis in adults and its relation to allergic rhinitis, asthma, and nasal polyps. J Allergy Clin Immunol 1988; 82: 950-956.
6. Anonymous. Data book for patients' population in Japan by the reports from the Statistics and Information Department of Japan, Ministry of Health and Welfare. Tokyo: Koseitokeikyokai, 1996.
7. Majima Y, Sakakura Y, Matsuibara T et al. Rheological properties of middle ear effusions from children with otitis media with effusion. Ann Otol Rhinol Laryngol 1986; 95 (supplement 124): 1-4.
8. Shin CK, Litt M, Khan MA, Wolf DP. Effect of nondialyzable solid concentration and viscoelasticity on ciliary transport of tracheal mucus. Am Rev Respir Dis 1977; 115: 989-995.
9. Majima Y, Sakakura Y. Rheological aspects of mucociliary clearance. In: Pass'ali D (ed). Rhinology up-to-date. Rome: Industria Grafica Romana, 1994; pp. 127-137.
10. Majima Y, Sakakura Y, Hattori M, Hirata K. Rheologic properties of nasal mucus from patients with chronic sinusitis. Am J Rhinology 1993; 7: 217-221.
11. Tatenuma T, Yasuoka S, Ogura T, Majima Y, Sakakura Y. Relationship between dynamic viscoelasticity and biochemical parameters in whole sputum from patients with hypersecretory respiratory diseases. Tokushima J Exp Med 1991; 38: 49-59.
12. Majima Y, Harada T, Shimizu T et al. Effect of biochemical components on rheologic properties of nasal mucus in chronic sinusitis. Am J Respir Crit Care Med 1999; 160: 421-426.
13. Carlstedt I, Sheehan JK. Macromolecular properties and polymetic structure of mucus glycoproteins. In: Ciba foundation symposium 109: Mucus and mucosa. London: The Pitman Press, 1984; pp. 157-172.
14. Ziment I, Mucokinetic agents. In: Respiratory pharmacology and therapeutics. Philadelphia: W. B. Saunders Company, 1978; pp. 60-104.
15. Sheffner AL. The reduction in vitro in viscosity of nucleoprotein solutions by a new mucolytic agent, N-acetyl-L-cysteine. Ann N Y Acad Sci 1963; 106: 298-310.
16. Rhee CS, Majima Y, Cho JS, Arima S, Min YG, Sakakura Y. Effects of mucokinetic drugs on rheological properties of reconstituted human nasal mucus. Arch Otolaryngol Head Neck Surg 1999; 125: 101-105.
17. Yuta A, Baraniuk JN. Therapeutic approaches to airway mucus hypersecretion. In: Rogers DF, Lethem MI (eds). Airway mucus: basic mechanisms and clinical perspectives. Basel: Birkhauser Verlag, 1997; pp. 365-383.
18. Majima Y, Hirata K, Takeuchi K, Hattori M, Sakakura Y. Effects of orally administered drugs on dynamic viscoelasticity of human nasal mucus. Am Rev Respir Dis 1990; 141: 79-83.
19. Lorber A, Chang CC, Matsuoka D, Meacham I. Effect of thiols in biological systems on protein sulfhydryl content. Biochem Pharmacol 1970; 19: 1551-1560.
20. Goodman RM, Yergin BM, Sackner MA. Effect of S-carboxymethyl-cysteine on tracheal mucus velocity. Chest 1978; 74: 615-618.
21. Stern M, Alton EW. Therapeutic approaches to the lung problems in cystic fibrosis. In: Rogers DF, Lethem MI (eds). Airway mucus: basic mechanisms and clinical perspectives. Basel: Birkhauser Verlag, 1997; pp. 342-364.
22. Zahm JM, Girod de Bentzmann S, Deneuville E et al. Dose-dependent in vitro effect of recombinant human DNase on the rheological and transport properties of cystic fibrosis respiratory mucus. Eur Respir J 1995; 8: 381-386.
23. Puchelle E, Zahm JM, de Bentzmann S et al. Effects of rhDNase on purulent airway secretions in chronic bronchitis. Eur Respir J 1996; 9: 765-769.
24. Vasconcellos CA, Allen PG, Wohl ME, Drazen JM, Janmey PA, Stossel TP. Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 1994; 263: 969-971.
25. Lethem MI, James SL, Marriott C, Burke JF. The origin of DNA associated with mucus glycoproteins in cystic fibrosis sputum. Eur Respir J 1990; 3: 19-23.
26. Lee HS, Majima Y, Sakakura Y, Shinogi J, Kawaguchi S, Kim BW. Quantitative cytology of nasal secretions under various conditions. Laryngoscope 1993; 103: 533-537.
27. King M, Engel LA, Macklem PT. Effect of pentobarbital anesthesia on rheology and transport of canine tracheal mucus. J Appl Physiol 1979; 46: 504-509.
28. Braga PC, Bossi R, Allegra L. Effects of serratio-peptidase on mucociliary clearance in patients with chronic bronchitis. Curr Ther Res 1981; 29: 738-744.
29. Takahashi Y, Shimizu T, Sakakura Y. Effects of indomethacin, dexamethasone, and erythromycin on endotoxine-induced intra-epithelial mucus production of rat nasal epithelium. Ann Otol Rhinol Laryngol 1977; 106: 683-687.
30. Lundgren JD, Hirata F, Marom Z et al. Dexamethasone inhibits respiratory glycoconjugate secretion from feline airways in vitro by the reduction of lipocortin (lipomodulin) synthesis. Am Rev Respir Dis 1988; 137: 353-357.
31. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 1995; 270: 283-290.
32. Li D, Gallup M, Fan N, Szymkowski DE, Basbaum CB. Cloning of the amino-terminal and 5′-flanking region of the human MUC5AC mucin gene and transcriptional up-regulation by bacterial exoproducts. J Biol Chem 1998; 273: 6812-6820.
33. Kadota J, Sakito O, Kohno S et al. A mechanism of erythromycin treatment in patients with diffuse panbronchitis. Am Rev Respir Dis 1993; 147: 153-159.
34. Moriyama H, Yanagi K, Ohtori N, Fukami M. Evaluation of endoscopic sinus surgery for chronic sinusitis: post-operative erythromycin therapy. Rhinology 1995; 33: 166-170.
35. Roche Y, Gougerot-Pocidalo MA, Fay N, Pocidalo JJ. Maclorides and immunity: effects of erythromycin and spiramycin on human mononuclear cell proliferation. J Antimicrob Chemother 1986; 17: 195-203.
36. Anderson R. Erythromycin and roxithromycin potentiate human neutrophil locomotion in vitro by inhibition of leukoattractant-activated superoxide generation and auto-oxidation. J Infect Dis 1989; 159: 966-973.
37. Goswami SK, Kivity S, Marom Z. Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro. Am Rev Respir Dis 1990; 141: 72-78.
38. Tamaoki J, Isono K, Sakai N, Kanemura T, Konno K. Erythromycin inhibits CI secretion across canine tracheal epithelial cells. Eur Respir J 1992, 5: 234-238.
39. Tamaoki J, Takeyama K, Tagaya E, Konno K. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob Agents Chemother 1995; 39: 1688-1690.
40. Rhee CS, Majima Y, Arima S et al. Effects of clarithromycin on rheological properties of nasal mucus in patients with chronic sinusitis. Ann Otol Rhinol Laryngol 2000; 109: 484-487.
41. Rubin BK, Druce H, Ramirez OE, Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med 1997; 155: 2018-2023.
42. Puchelle E, Zahm JM, Duvivier C. Spin, spinability of bronchial mucus. Relationship with viscoelasticity and mucous transport properties. Biorheology 1983; 20: 239-249.
43. Desaki M, Takizawa H, Ohtoshi T et al. Erythromycin suppresses nuclear factor-κB and activator protein-I activation in human bronchial epithelial cells. Biochem Biophys Res Commun 2000; 267: 124-128.
44. Majima Y, Sakakura Y, Matsubara T, Murai S, Miyoshi Y. Mucociliary clearance in chronic sinusitis: related human nasal clearance and in vitro bullfrog palate clearance. Biorheology 1983; 20: 251-262.